Navigation Links
Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
Date:1/19/2010

82046177';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.endo.com/">www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release.  These factors include, but are not limited to: the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in ma
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:9/1/2015)... ... September 01, 2015 , ... Award-winning adult film ... about their experiences of female beauty, women’s emotions, fertility, female violence and sexual ... well as their relationships with other men, documenting how the power balance between ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Anthony J. ... the Super Lawyers 2015 for his third consecutive year in a row. Through ... accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is a ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In America”, hosted ... at the topic of arthritis. There are over 100 different types of arthritis. One ... and statistics in an effort to shed light on this important topic. , Anyone ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and Lightning ... stickers to keep little ones' safety top of mind at all times. , Sponsored ... focus. According to the JPMA's Baby Safety Zone website, this year's theme is A ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... PRESENT e-Learning Systems, has become a leader in podiatric, surgical ... education. The Superbones Superwounds Conferences place top national speakers at the podium and ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2
... Nov. 18 Sleep Health Centers , a leading provider ... announce the formation of SleepPartners ( www.sleeppartners.com ) ... board-certified sleep specialists and a focus on superior sleep disorder ... their geographic reach extends high quality sleep medicine services throughout ...
... 18 Banfield, The Pet Hospital® today announced ... its medical specialist/nutritionist. With nearly 20 years experience in veterinary ... platform that will position Banfield as a leader in veterinary ... as part of the Medical Quality Advancement team at Banfield,s ...
... Medspira, and Mayo Clinic have entered into an ... developed products and technologies invented by Mayo physicians and ... agreement are two Radiology products currently available in the ... MRI Coils, and two technologies that Medspira will develop ...
... scientists have significantly advanced our understanding of dopamine release ... of more effective drugs for treating Parkinson,s Disease. ... tremor, a slowing of physical movement and, in extreme ... are caused by the loss of dopamine producing nerve ...
... the B vitamin didn,t reverse or stall carotid artery ... the B vitamin niacin offers no additional benefit to ... cholesterol-lowering statin drugs, U.S. researchers say. , The 18-month ... 65 found no measurable difference in arterial wall thickness ...
... what women should do about the new guidelines, , WEDNESDAY, ... force recommended that women wait until they,re 50 to get ... swift. , Critics such as the American Cancer Society vowed ... age 40 for women of average risk. The American ...
Cached Medicine News:Health News:Sleep HealthCenters Launches SleepPartners(TM) Network 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 3Health News:Medspira and Mayo Clinic Enter Into Agreement 2Health News:Medspira and Mayo Clinic Enter Into Agreement 3Health News:Findings that should speed the development of drugs for Parkinson's disease 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2Health News:Mammography: What to Do Now? 2Health News:Mammography: What to Do Now? 3Health News:Mammography: What to Do Now? 4
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: